Grant: Canadian Lung Association Research Studentship
University of Toronto
$19,000.00
Modeling human iPSC-derived alveolar type 1 and 2 cells for respiratory diseases
EF 2022-23
Résumé
This is a multi-disciplinary collaboration involving experts in stem cell and developmental biology, bioengineering, bioinformatics and mathematical modeling. We will use innovative techniques including stem cell organoids, cellular barcoding, single-cell omics, and microfluidic-based engineered platforms.
In the human lung, human breath (respiration) and gas exchange occur primarily in the human alveolar sacs (balloon-like structure) which are covered by alveolar epithelial cells including alveolar type 1 and type 2 cells (AT1, AT2). These AT1 and AT2 cells are derived from alveolar bipotent progenitor cells (BPC) in human fetal and adult lungs and are implicated in several lung diseases such as childhood interstitial lung diseases (CHILD), respiratory viral infections, and Cystic Fibrosis. However, it is hard to access the primary patient-specific alveolar cells to have biomedical research. Hence, developing a model which can produce alveolar cell types from human induced pluripotent stem cells iPSC (cells can limitlessly develop into any type of human cell) is very important. Recent developments in producing alveolar cell types from iPSCs have shown some efficacy in generating immature or fetal alveolar-like cell types. Also, expansion and maintenance of BPCs derived from iPSC as well as the ability to further push these cells to maturation to form bona fide respiratory AT1 and AT2 cells remain a challenge. We recently developed a new method to generate bipotent alveolospheres from BPCs. While these alveolospheres are renewable for several passages, current air-liquid-interface culture conditions (alveolar cells expose to air) are incapable of efficiently maturing these cells.
The goal of this study is to identify physiological parameters that can be used to mature AT1/AT2 cells in culture for eventual use in regenerative medicine and to understand the lineage relationships during the differentiation of BPCs in alveolospheres.
The BPCs from alveolospheres will be exposed to three different microfluidic platforms that mimic post-natal life by considering different physiological parameters including airflow (cyclic stretch) (A), fluid flow (shear stress) (B), and surface stretch (C) to further mature into AT1 and AT2 cells. The unique sequence tags (DNA barcodes) will be introduced into each of the BPCs in alveolospheres to allow us to follow the cell lineage maturation process to trace the lineage relationship of BPCs.
The success of this project will provide an important resource of respiratory cells for personalized disease modeling, precision drug screening, or regeneration as a treatment strategy for lung diseases.
Programme
Canadian Lung Association Research Studentship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
476988
Name
Song Yuetong
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Lung Association (Ottawa)
Prcname2
Special Cases
Projecttitle
Modeling human iPSC-derived alveolar type 1 and 2 cells for respiratory diseases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$19,000
Cihrequipment2
$0
Programname2
Canadian Lung Association Research Studentship
Keyworddelim
Alveolar Epithelium; Disease Modeling; Induced Pluripotent Stem Cell; Lineage Tracing; Microfluidic Device
Abstract
This is a multi-disciplinary collaboration involving experts in stem cell and developmental biology, bioengineering, bioinformatics and mathematical modeling. We will use innovative techniques including stem cell organoids, cellular barcoding, single-cell omics, and microfluidic-based engineered platforms.
In the human lung, human breath (respiration) and gas exchange occur primarily in the human alveolar sacs (balloon-like structure) which are covered by alveolar epithelial cells including alveolar type 1 and type 2 cells (AT1, AT2). These AT1 and AT2 cells are derived from alveolar bipotent progenitor cells (BPC) in human fetal and adult lungs and are implicated in several lung diseases such as childhood interstitial lung diseases (CHILD), respiratory viral infections, and Cystic Fibrosis. However, it is hard to access the primary patient-specific alveolar cells to have biomedical research. Hence, developing a model which can produce alveolar cell types from human induced pluripotent stem cells iPSC (cells can limitlessly develop into any type of human cell) is very important. Recent developments in producing alveolar cell types from iPSCs have shown some efficacy in generating immature or fetal alveolar-like cell types. Also, expansion and maintenance of BPCs derived from iPSC as well as the ability to further push these cells to maturation to form bona fide respiratory AT1 and AT2 cells remain a challenge. We recently developed a new method to generate bipotent alveolospheres from BPCs. While these alveolospheres are renewable for several passages, current air-liquid-interface culture conditions (alveolar cells expose to air) are incapable of efficiently maturing these cells.
The goal of this study is to identify physiological parameters that can be used to mature AT1/AT2 cells in culture for eventual use in regenerative medicine and to understand the lineage relationships during the differentiation of BPCs in alveolospheres.
The BPCs from alveolospheres will be exposed to three different microfluidic platforms that mimic post-natal life by considering different physiological parameters including airflow (cyclic stretch) (A), fluid flow (shear stress) (B), and surface stretch (C) to further mature into AT1 and AT2 cells. The unique sequence tags (DNA barcodes) will be introduced into each of the BPCs in alveolospheres to allow us to follow the cell lineage maturation process to trace the lineage relationship of BPCs.
The success of this project will provide an important resource of respiratory cells for personalized disease modeling, precision drug screening, or regeneration as a treatment strategy for lung diseases.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Song, Yuetong
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Circ &Respiratory Hlth~ $19,000~ $0~